COMP <GO>
TEVA vs JNJ // NET PROFIT MARGIN
Teva Pharmaceutical Industries Limited (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: TEVA 2
— JNJ 11
▲ NET PROFIT MARGIN LEADER: JNJ
LAST: $42.09 (+1.50%) • MKT CAP: $48.32B
net-margins
8.20%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
net-margins
28.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TEVA VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TEVA | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 51.80% | 67.90% | -16.10 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.40% | 25.50% | -16.10 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.8x | 18.5x | +2.30 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 1.81% | 2.97% | -1.16 | JNJ | /fcf-yield <GO> |
| Operating Margin | 12.50% | 34.70% | -22.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 8.20% | 28.50% | -20.30 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | 6.00% | -1.70 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.02 | 5.59 | -4.57 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.20% | -0.30 | TEVA | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.7 | 60.4 | +3.33 | TEVA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.08 | -0.08 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.9x | 23.0x | +8.90 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $48.32B | $662.49B | -$614.17B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TEVA REV | JNJ REV | TEVA GROSS % | JNJ GROSS % | TEVA FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $17.26B | $94.19B | 51.8% | 67.9% | $872.4M | $19.70B |
| FY 2024 | $16.54B | $88.82B | 48.7% | 69.1% | $502.5M | $19.84B |
| FY 2023 | $15.85B | $85.16B | 44.0% | 44.0% | $654.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TEVA // BETA 1.00
JNJ // BETA 1.08